Published in

Karger Publishers, Chemical Immunology and Allergy, p. 197-215, 2013

DOI: 10.1159/000353255

BioMed Central, Journal of Hematology and Oncology, 1(3), 2010

DOI: 10.1186/1756-8722-3-26

Taylor & Francis, Expert Opinion on Pharmacotherapy, 2(11), p. 233-247

DOI: 10.1517/14656560903451716

Links

Tools

Export citation

Search in Google Scholar

Angiogenesis inhibitors in the treatment of prostate cancer

Journal article published in 2010 by Paul G. Kluetz, Fatima H. Karzai, Clara Hwang ORCID, Bamidele A. Adesunloye, William D. Figg, William L. Dahut, Elisabeth I. Heath
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Prostate cancer remains a significant public health problem, with limited therapeutic options in the setting of castrate-resistant metastatic disease. Angiogenesis inhibition is a relatively novel antineoplastic approach, which targets the reliance of tumor growth on the formation of new blood vessels. This strategy has been used successfully in other solid tumor types, with the FDA approval of anti-angiogenic agents in breast, lung, colon, brain, and kidney cancer. The application of anti-angiogenic therapy to prostate cancer is reviewed in this article, with attention to efficacy and toxicity results from several classes of anti-angiogenic agents. Ultimately, the fate of anti-angiogenic agents in prostate cancer rests on the eagerly anticipated results of several key phase III studies.